Lung Cancer News and Research

Latest Lung Cancer News and Research

Endobronchial ultrasound: More precise and less invasive than other lung cancer staging methods

A new technique being used by thoracic surgeons at Rush University Medical Center offers a more precise, less invasive and more versatile way of assessing a patient's lymph nodes and chest tumors to determine if lung cancer has spread to other parts of the body.

16 Mar 2010

Poniard Pharmaceuticals sells over 4.2M common shares to Commerce Court Small Cap Value Fund

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the sale of 4,229,000 of its common shares to Commerce Court Small Cap Value Fund, Ltd. for gross proceeds of approximately $6.3 million, or approximately $1.49 per share, under its existing committed equity financing facility with Commerce Court.

16 Mar 2010

CytRx plans five Phase 2 clinical trials with oncology drug candidates

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the twelve months ended December 31, 2009, and affirmed its 2010 milestones of commencing up to five Phase 2 clinical trials with its oncology drug candidates.

15 Mar 2010

Prioritizing end of life care for cancer patients

Despite the advances and groundbreaking research being performed in the area of cancer treatment, sometimes cancer cannot be cured. In this situation, patients and their families are faced with complex emotions and a variety of end of life issues and decisions.

15 Mar 2010

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.

12 Mar 2010

Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC

Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).

12 Mar 2010

OXiGENE signs definitive agreement to sell Common Stock

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has entered into a definitive agreement with certain institutional investors to sell 6,578,945 shares of its Common Stock and separate series of warrants to purchase Common Stock in a private placement.

12 Mar 2010

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended January 31, 2010. The company also provided an update on its clinical programs and corporate developments.

From Thermo Fisher Scientific Inc. 11 Mar 2010

ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

ImmunoCellular Therapeutics, Ltd. announced today that its dendritic cell-based vaccination with cancer stem cells demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma.

11 Mar 2010

Biomoda, Obio collaborate to expand Biomoda’s lung cancer screening program for veterans into Ohio

Cancer diagnostics company Biomoda, Inc. (www.biomoda.com) and Obio, Inc., a corporation formed to pursue public and private funding for cancer research in Ohio, are working together to expand Biomoda’s lung cancer screening program for veterans into Ohio.

10 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Children's Hospital Boston develops new web site, releases video message on current state of stem cell research

Exactly one year to the day after President Obama's historic decision to reverse an eight-year restriction on federally funded embryonic stem cell research, the Children's Hospital Boston Stem Cell Program today announced the development of a unique, comprehensive web site and released a candid video message from its top researchers on the current state of stem cell research to introduce the new site: stemcell.childrenshospital.org.

10 Mar 2010

Team Lung Love: New endurance sports training program focused on raising awareness for lung cancer

Lung Cancer Alliance announced the launch of Team Lung Love (TLL), an endurance sports training program focused exclusively on raising awareness and support for lung cancer.

10 Mar 2010

Celebrity supports fundraising event for cancer research

Kimberly Wyatt from the "Pussycat Dolls" has shone brightly to promote Cancer Research UK's latest fundraising event by posing in a bespoke, illuminated dress designed especially for her.

10 Mar 2010

Genetic variant increases risk of lung cancer for light and heavy smokers, say researchers

Individuals with a certain type of genetic susceptibility to lung cancer face a greatly increased risk for the deadly disease with even a small exposure to cigarette smoke, a study team that includes researchers from the University of Cincinnati has concluded.

10 Mar 2010

National Asbestos Awareness Week to raise awareness about prevalence of asbestos-related diseases

The Asbestos Disease Awareness Organization, the leading organization serving as the voice of asbestos victims, today applauds Representative Steve Cohen (D-TN - 09) and cosponsors for introducing a resolution that declares the first week of April as “National Asbestos Awareness Week” and seeks to “raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure.”

9 Mar 2010

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.

8 Mar 2010

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009.

8 Mar 2010

iCAD granted patent covering SecondLook Digital CAD solution incorporating lesion metrics

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, announces that the United States Patent and Trademark Office recently granted the company Patent Number 7,660,448. This patent covers future iterations of iCAD’s SecondLook® Digital Computer-Aided Detection (CAD) solution with potential application to the company’s other image analysis solutions.

8 Mar 2010

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today at the 2010 American Society of Clinical Oncology's Genitourinary Cancers Symposium in San Francisco, CA.

6 Mar 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

Endobronchial ultrasound: More precise and less invasive than other lung cancer staging methods

Poniard Pharmaceuticals sells over 4.2M common shares to Commerce Court Small Cap Value Fund

CytRx plans five Phase 2 clinical trials with oncology drug candidates

Prioritizing end of life care for cancer patients

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC

OXiGENE signs definitive agreement to sell Common Stock

Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45%

ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

Biomoda, Obio collaborate to expand Biomoda’s lung cancer screening program for veterans into Ohio

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Children's Hospital Boston develops new web site, releases video message on current state of stem cell research

Team Lung Love: New endurance sports training program focused on raising awareness for lung cancer

Celebrity supports fundraising event for cancer research

Genetic variant increases risk of lung cancer for light and heavy smokers, say researchers

National Asbestos Awareness Week to raise awareness about prevalence of asbestos-related diseases

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

iCAD granted patent covering SecondLook Digital CAD solution incorporating lesion metrics

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in